Word: genentech
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...foot-and-mouth may finally be checked. Last week Agriculture Secretary John Block announced that researchers from the California gene-splicing firm Genentech, Inc., in collaboration with his department's scientists, had produced a safe, effective vaccine against the disease. Like polio viruses, the tiny virus that causes foot-and-mouth has a coating of four proteins. A team of Agriculture Department scientists, led by Biochemist Howard Bachrach, had isolated one of them, calling it VP3 (for virus protein). Injecting the substance into test animals, they found it created immunity without causing infection. But using it was risky, because...
When stock in Cetus Corp., one of the world's four major genetic engineering firms, was offered to the public three months ago, investors eagerly bought 5.2 million shares at $23, but the price has since declined to $19. Just a half year earlier, shares of competing Genentech jumped within minutes on the first day of trading from $35 to a stratospheric $89. But now Genentech stock is selling for only $37 a share. Has the genie gone out of genetic-engineering companies...
Across the Bay Bridge in South San Francisco, Genentech is in the midst of a $20 million expansion. The firm's gene-spliced insulin, which is thought less likely to produce an allergic reaction in some diabetics than the animal insulin usually used, is now in the final phase of certification by the Food and Drug Adminstration. It could be put on the market perhaps by late 1982. But Genentech is .rying to iron out some difficult problems with the human growth hormone used to treat dwarfs. Patients at Stanford University's hospital a few weeks ago developed...
Genetic engineering, an ensemble of techniques to join bits of DNA and insert them into bacteria to make large quantities of potentially valuable proteins, made a great splash last year when stock from Genentech Inc. went public and jumped $45 per share during its first day on the market. The slightest technological advance still sends prices leaping. Genentech jumped $7 in one day two weeks ago when workers announced a new process to make interferon, a supposed cancer-fighting protein. Genentech will now use yeast to produce the human protein rather than bacteria. It doesn't seem like a major...
This technological advance becomes more attractive to Genentech stockholders when you realize that the company began human clinical trials of interferon two months ago in conjunction with the pharmaceutical house Hoffman-Larouche. Eight advanced cancer patients in Houston are now being treated with interferon under the aegis of the National Cancer Institute...